Respiratory Drug Delivery Market leading companies are Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.)
Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis. The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. The respiratory drug delivery market , based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles. Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therap...